ATE332965T1 - Komplementierende zellinien - Google Patents
Komplementierende zellinienInfo
- Publication number
- ATE332965T1 ATE332965T1 AT01996603T AT01996603T ATE332965T1 AT E332965 T1 ATE332965 T1 AT E332965T1 AT 01996603 T AT01996603 T AT 01996603T AT 01996603 T AT01996603 T AT 01996603T AT E332965 T1 ATE332965 T1 AT E332965T1
- Authority
- AT
- Austria
- Prior art keywords
- sequences
- human
- cell line
- cell lines
- adenovirus
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/861—Adenoviral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/02—Recovery or purification
- C12N7/025—Packaging cell lines, e.g. transcomplementing cell lines, for production of virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10041—Use of virus, viral particle or viral elements as a vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10051—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10351—Methods of production or purification of viral material
- C12N2710/10352—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Electrochromic Elements, Electrophoresis, Or Variable Reflection Or Absorption Elements (AREA)
- Transducers For Ultrasonic Waves (AREA)
- Surface Acoustic Wave Elements And Circuit Networks Thereof (AREA)
- Design And Manufacture Of Integrated Circuits (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/713,678 US6492169B1 (en) | 1999-05-18 | 2000-11-15 | Complementing cell lines |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE332965T1 true ATE332965T1 (de) | 2006-08-15 |
Family
ID=24867049
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT01996603T ATE332965T1 (de) | 2000-11-15 | 2001-11-14 | Komplementierende zellinien |
Country Status (13)
Country | Link |
---|---|
US (8) | US6492169B1 (de) |
EP (1) | EP1349926B1 (de) |
JP (1) | JP4402881B2 (de) |
AT (1) | ATE332965T1 (de) |
AU (2) | AU1856902A (de) |
CA (1) | CA2428739C (de) |
CY (1) | CY1105232T1 (de) |
DE (1) | DE60121471T2 (de) |
DK (1) | DK1349926T3 (de) |
ES (1) | ES2267864T3 (de) |
NZ (1) | NZ525997A (de) |
PT (1) | PT1349926E (de) |
WO (1) | WO2002040665A2 (de) |
Families Citing this family (139)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI0833934T2 (sl) * | 1995-06-15 | 2013-04-30 | Crucell Holland B.V. | Pakirni sistemi za humani rekombinantni adenovirus za uporabo v genski terapiji |
US6783980B2 (en) * | 1995-06-15 | 2004-08-31 | Crucell Holland B.V. | Packaging systems for human recombinant adenovirus to be used in gene therapy |
US20040043489A1 (en) * | 1998-07-08 | 2004-03-04 | Menzo Havenga | Gene delivery vectors provided with a tissue tropism for dendritic cells and methods of use |
US20030017138A1 (en) * | 1998-07-08 | 2003-01-23 | Menzo Havenga | Chimeric adenoviruses |
US6929946B1 (en) * | 1998-11-20 | 2005-08-16 | Crucell Holland B.V. | Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells |
US20050170463A1 (en) * | 1999-04-15 | 2005-08-04 | Abraham Bout | Recombinant protein production in permanent amniocytic cells that comprise nucleic acid encoding adenovirus E1A and E1B proteins |
US7604960B2 (en) * | 1999-04-15 | 2009-10-20 | Crucell Holland B.V. | Transient protein expression methods |
US6855544B1 (en) * | 1999-04-15 | 2005-02-15 | Crucell Holland B.V. | Recombinant protein production in a human cell |
US20050164386A1 (en) * | 1999-04-15 | 2005-07-28 | Uytdehaag Alphonsus G. | Overexpression of enzymes involved in post-translational protein modifications in human cells |
US7297680B2 (en) * | 1999-04-15 | 2007-11-20 | Crucell Holland B.V. | Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content |
US8236561B2 (en) * | 1999-04-15 | 2012-08-07 | Crucell Holland B.V. | Efficient production of IgA in recombinant mammalian cells |
US20050232900A1 (en) * | 1999-05-18 | 2005-10-20 | Crucell Holland B.V. | Serotype of adenovirus and uses thereof |
US6492169B1 (en) | 1999-05-18 | 2002-12-10 | Crucell Holland, B.V. | Complementing cell lines |
US6913922B1 (en) * | 1999-05-18 | 2005-07-05 | Crucell Holland B.V. | Serotype of adenovirus and uses thereof |
US7192759B1 (en) * | 1999-11-26 | 2007-03-20 | Crucell Holland B.V. | Production of vaccines |
US7521220B2 (en) * | 1999-11-26 | 2009-04-21 | Crucell Holland B.V. | Production of vaccines |
US7527961B2 (en) * | 1999-11-26 | 2009-05-05 | Crucell Holland B.V. | Production of vaccines |
EP1157999A1 (de) * | 2000-05-24 | 2001-11-28 | Introgene B.V. | Verfahren und Mitteln zur Verbesserung der Haut-Transplantation mittels Genabgabe-Vehikel mit Tropismus für primären Fibroblasten, sowie andere Verwendungsmöglichkeiten für diesen |
EP1322774A2 (de) * | 2000-09-20 | 2003-07-02 | Crucell Holland B.V. | Transduktion von dendritischen zellen durch verwendung der adenovirenvektoren |
DE60138403D1 (de) * | 2000-09-26 | 2009-05-28 | Crucell Holland Bv | Adenovirale vektoren für die übertragung von genen in zellen der skelettmuskulatur oder myoblasten |
ATE384785T1 (de) * | 2001-12-07 | 2008-02-15 | Crucell Holland Bv | Herstellung von viren, virusisolaten, und impfstoffen |
CA2478508C (en) * | 2002-04-25 | 2013-07-02 | Crucell Holland B.V. | Stable adenoviral vectors and methods for propagation thereof |
CA2477954C (en) * | 2002-04-25 | 2012-07-10 | Crucell Holland B.V. | Means and methods for the production of adenovirus vectors |
CN100471957C (zh) * | 2002-04-30 | 2009-03-25 | 艾维亚医药/生物技术有限公司 | 用于免疫治疗的腺病毒载体 |
JP4237449B2 (ja) * | 2002-06-05 | 2009-03-11 | 国立医薬品食品衛生研究所長 | アデノウィルスベクター |
US20080153083A1 (en) * | 2003-10-23 | 2008-06-26 | Crucell Holland B.V. | Settings for recombinant adenoviral-based vaccines |
EP1553983A2 (de) | 2002-10-23 | 2005-07-20 | Crucell Holland B.V. | Einstellung für rekombinante adenovirus-basierte impfstoffe |
US9388427B2 (en) * | 2002-12-02 | 2016-07-12 | Biovec, Llc | In vivo and ex vivo gene transfer into renal tissue using gutless adenovirus vectors |
EP1573012B1 (de) | 2002-12-17 | 2011-11-30 | Crucell Holland B.V. | Rekombinanter virus-basierter malaria impfstoff |
EP1611237A1 (de) * | 2003-03-28 | 2006-01-04 | Merck & Co., Inc. | Adenovirus serotyp 34-vektoren, nukleinsäuren und so erzeugtes virus |
CN101328473B (zh) * | 2003-05-09 | 2012-05-02 | 克鲁塞尔荷兰公司 | E1-永生化的细胞培养物及培养所述细胞以提高从中获取的产物产量的方法 |
DK1626992T3 (da) * | 2003-05-23 | 2010-09-20 | Crucell Holland Bv | Produktion af rekombinant IgM i PER.C6-celler |
AU2004260044B2 (en) * | 2003-07-18 | 2009-04-23 | Onyx Pharmaceuticals, Inc. | Subgroup B adenoviral vectors for treating disease |
ES2359473T3 (es) | 2003-07-21 | 2011-05-23 | Transgene S.A. | Citoquinas multifuncionales. |
DK1670925T3 (da) * | 2003-10-02 | 2013-07-08 | Crucell Holland Bv | Pakningsceller til rekombinat adenovirus |
DK1780269T3 (da) * | 2004-02-23 | 2009-10-12 | Crucell Holland Bv | Virusrensningsmetoder |
DE202005022108U1 (de) | 2004-03-09 | 2013-11-12 | Novartis Vaccines And Diagnostics, Inc. | Influenza-Virus-Impfstoffe |
EP2811027A1 (de) | 2004-05-21 | 2014-12-10 | Novartis Vaccines and Diagnostics, Inc. | Alphavirus-Vektoren für RSV- und PIV-Impfstoffe |
US7608425B2 (en) | 2004-07-23 | 2009-10-27 | Immunomedics, Inc. | Methods for protein expression in mammalian cells in serum-free medium |
US7537930B2 (en) | 2004-07-23 | 2009-05-26 | Immunomedics, Inc. | Mammalian cell lines for increasing longevity and protein yield from a cell culture |
US7531327B2 (en) | 2004-07-23 | 2009-05-12 | Immunomedics, Inc. | Methods and compositions for increasing longevity and protein yield from a cell culture |
AP2351A (en) | 2004-10-13 | 2012-01-25 | Crucell Holland Bv | Improved adenoviral vectors and uses thereof. |
SG159554A1 (en) | 2004-11-16 | 2010-03-30 | Crucell Holland Bv | Multivalent vaccines comprising recombinant viral vectors |
EP2573186A1 (de) | 2004-12-08 | 2013-03-27 | MedImmune, LLC | Verfahren zur Herstellung von Influenza-Impfstoffzusammensetzungen |
AU2012216357B2 (en) * | 2005-04-11 | 2014-01-30 | Purdue Research Foundation | Vaccine against pandemic strains of influenza viruses |
DE602006003420D1 (de) * | 2005-04-11 | 2008-12-11 | Crucell Holland Bv | Virusreinigung mit ultrafiltration |
KR20080052512A (ko) * | 2005-05-23 | 2008-06-11 | 박신, 인크. | 아데노바이러스-무함유 재조합 아데노바이러스 벡터의 급속생산 |
AU2006202209B2 (en) * | 2005-05-27 | 2011-04-14 | Lifescan, Inc. | Amniotic fluid derived cells |
PT2301572E (pt) | 2005-11-01 | 2014-12-22 | Novartis Vaccines & Diagnostic | Vacinas virais derivadas de células com níveis baixos de adn celular residual |
DE102005054628A1 (de) * | 2005-11-16 | 2007-05-24 | Cevec Pharmaceuticals Gmbh | Verfahren zur Herstellung von permanenten humanen Zelllinien |
WO2007104792A2 (en) * | 2006-03-16 | 2007-09-20 | Crucell Holland B.V. | Recombinant adenoviruses based on serotype 26 and 48, and use thereof |
EP1998804B1 (de) * | 2006-03-27 | 2014-04-16 | Crucell Holland B.V. | Zusammensetzungen, die einen rekombinanten adenovirus und ein adjuvans umfassen |
US9254318B2 (en) | 2006-03-31 | 2016-02-09 | Wisconsin Alumni Research Foundation | High titer recombinant influenza viruses for vaccines |
CA2654324A1 (en) | 2006-06-02 | 2007-12-13 | International Aids Vaccine Initiative | Hiv-1 clade a consensus sequences, antigens, and transgenes |
EP2426142A3 (de) | 2006-10-16 | 2012-06-13 | Genelux Corporation | Modifizierte Impfstoffvirusstämme zur Verwendung in einem Diagnose- und Therapieverfahren |
EP2390340A3 (de) | 2007-01-30 | 2012-02-22 | Transgene SA | Papillomavirus E1 und E2-Polypeptiden mit reduziertem Identitätsanteil kodierender Vektor |
WO2008112540A2 (en) * | 2007-03-09 | 2008-09-18 | Vectorlogics, Inc. | Cells for adenovirus vector and protein production |
US9474798B2 (en) | 2007-06-18 | 2016-10-25 | Wisconsin Alumni Research Foundation | Influenza M2 protein mutant viruses as live influenza attenuated vaccines |
US8871515B2 (en) * | 2008-09-17 | 2014-10-28 | Isogenis, Inc. | Construction of fully-deleted adenovirus-based gene delivery vectors and uses thereof |
KR101504392B1 (ko) * | 2008-11-03 | 2015-03-19 | 크루셀 홀란드 비.브이. | 아데노바이러스 벡터의 제조방법 |
PL2382474T3 (pl) | 2009-01-20 | 2015-08-31 | Transgene Sa | Rozpuszczalny ICAM-1 jako biomarker do prognozowania odpowiedzi terapeutycznej |
KR20110138354A (ko) | 2009-03-24 | 2011-12-27 | 트랜스진 에스.에이. | 환자를 모니터링하기 위한 바이오마커 |
SG175060A1 (en) | 2009-04-17 | 2011-11-28 | Transgene Sa | Biomarker for monitoring patients |
HUE028240T2 (en) | 2009-07-10 | 2016-12-28 | Transgene Sa | Biomarker Patient Selection and Related Procedures |
KR20120052352A (ko) | 2009-08-07 | 2012-05-23 | 트랜스진 에스.에이. | Hbv 감염을 치료하는 조성물 |
EP2488635B1 (de) | 2009-10-15 | 2013-11-20 | Crucell Holland B.V. | Verfahren zur Adenovirus-Reinigung aus Kulturen mit hoher Zelldichte |
CN102791852B (zh) | 2009-10-15 | 2014-05-07 | 克鲁塞尔荷兰公司 | 纯化腺病毒颗粒的方法 |
US9109013B2 (en) | 2009-10-26 | 2015-08-18 | Wisconsin Alumni Research Foundation | High titer recombinant influenza viruses with enhanced replication in vero cells |
US20120309056A1 (en) | 2010-02-04 | 2012-12-06 | Leon Arnaud | Fed-batch process using concentrated cell culture medium for the efficient production of biologics in eb66 cells |
AU2011214262B2 (en) | 2010-02-15 | 2015-05-21 | Crucell Holland B.V. | Method for the production of Ad26 adenoviral vectors |
US10130697B2 (en) | 2010-03-23 | 2018-11-20 | Wisconsin Alumni Research Foundation (Warf) | Vaccines comprising mutant attenuated influenza viruses |
WO2011139717A1 (en) | 2010-04-26 | 2011-11-10 | Novartis Ag | Improved production of virus replicon particles in packaging cells |
SG187863A1 (en) * | 2010-08-16 | 2013-03-28 | Cevec Pharmaceuticals Gmbh | Permanent human amniocyte cell lines for producing influenza viruses |
WO2012038367A1 (en) | 2010-09-20 | 2012-03-29 | Crucell Holland B.V. | Therapeutic vaccination against active tuberculosis |
MX363307B (es) | 2010-10-11 | 2019-03-20 | Novartis Ag Star | Plataformas para suministro de antigenos. |
HUE043879T2 (hu) | 2011-01-26 | 2019-09-30 | Glaxosmithkline Biologicals Sa | RSV-immunizálási rend |
US9058175B2 (en) * | 2011-06-07 | 2015-06-16 | The Mathworks, Inc. | Parameter promotion in a block diagram modeling environment |
BR112014008694A2 (pt) | 2011-10-11 | 2017-06-20 | Novartis Ag | moléculas de ácido nucleico policistrônico recombinante |
EP2766385A2 (de) | 2011-10-12 | 2014-08-20 | Novartis AG | Cmv-antigene und verwendungen davon |
IN2014CN04742A (de) | 2011-11-28 | 2015-09-18 | Crucell Holland Bv | |
DK2825640T3 (en) | 2012-03-12 | 2016-08-01 | Crucell Holland Bv | BATCHES OF RECOMBINANT ADENOVIRUS WITH CHANGED TERMINAL END |
US8932607B2 (en) | 2012-03-12 | 2015-01-13 | Crucell Holland B.V. | Batches of recombinant adenovirus with altered terminal ends |
AP2014007993A0 (en) | 2012-03-22 | 2014-10-31 | Crucell Holland Bv | Vaccine against RSV |
US9125870B2 (en) | 2012-03-22 | 2015-09-08 | Crucell Holland B.V. | Vaccine against RSV |
US9442702B1 (en) | 2012-04-30 | 2016-09-13 | The Mathworks, Inc. | Overriding an interface in a graphical block diagram modeling environment |
EP2855685B1 (de) | 2012-05-24 | 2017-03-08 | Janssen Vaccines & Prevention B.V. | Adenovirale vektoren zur transduktion von vaskulärem gewebe |
EP2912069B1 (de) | 2012-10-23 | 2019-07-31 | Emory University | Gm-csf- und il-4-konjugate, zusammensetzungen und zugehörige verfahren |
CA3200425A1 (en) | 2012-11-16 | 2014-05-22 | Peter ABBINK | Recombinant adenoviruses and use thereof |
CN105188745B (zh) | 2013-04-25 | 2019-10-18 | 扬森疫苗与预防公司 | 稳定化的可溶性融合前rsv f多肽 |
EP3010931B1 (de) | 2013-06-17 | 2018-06-13 | Janssen Vaccines & Prevention B.V. | Stabilisierte lösliche präfusionierte rsv-f-polypeptide |
JP2016524915A (ja) | 2013-07-15 | 2016-08-22 | ウィスコンシン アルムニ リサーチ ファンデイション | Mdck、ベロ細胞又は卵内で増強された複製を有する高力価の組換えインフルエンザウイルス |
US9974737B2 (en) | 2013-09-19 | 2018-05-22 | Janssen Vaccines & Prevention B.V. | Adenovirus formulations |
WO2015077717A1 (en) | 2013-11-25 | 2015-05-28 | The Broad Institute Inc. | Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status |
WO2015085147A1 (en) | 2013-12-05 | 2015-06-11 | The Broad Institute Inc. | Polymorphic gene typing and somatic change detection using sequencing data |
CA2934073A1 (en) | 2013-12-20 | 2015-06-25 | The Broad Institute, Inc. | Combination therapy with neoantigen vaccine |
WO2015196150A2 (en) | 2014-06-20 | 2015-12-23 | Wisconsin Alumni Research Foundation (Warf) | Mutations that confer genetic stability to additional genes in influenza viruses |
AU2015252119A1 (en) | 2014-11-07 | 2016-05-26 | Takeda Vaccines, Inc. | Hand, foot, and mouth vaccines and methods of manufacture and use thereof |
AR102547A1 (es) | 2014-11-07 | 2017-03-08 | Takeda Vaccines Inc | Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y su uso |
EP3757211A1 (de) | 2014-12-19 | 2020-12-30 | The Broad Institute, Inc. | Verfahren zur profilierung des t-zell-rezeptor-repertoirs |
EP3234193B1 (de) | 2014-12-19 | 2020-07-15 | Massachusetts Institute of Technology | Molekulare biomarker für krebsimmuntherapie |
WO2016145150A2 (en) | 2015-03-11 | 2016-09-15 | The Broad Institute Inc. | Selective treatment of prmt5 dependent cancer |
AU2016249798B2 (en) | 2015-04-14 | 2022-05-26 | Janssen Vaccines And Prevention B.V. | Recombinant adenovirus expressing two transgenes with a bidirectional promoter |
RU2020132040A (ru) | 2015-05-20 | 2020-10-12 | Те Брод Инститьют Инк. | Общие неоантигены |
US10633422B2 (en) | 2015-06-01 | 2020-04-28 | Wisconsin Alumni Research Foundation (Warf) | Influenza virus replication by inhibiting microRNA lec7C binding to influenza viral cRNA and mRNA |
TW202241500A (zh) | 2015-06-09 | 2022-11-01 | 美商博德研究所有限公司 | 用於贅瘤疫苗之調配物及其製備方法 |
US9890363B2 (en) | 2015-07-06 | 2018-02-13 | Wisconsin Alumni Research Foundation (Warf) | Influenza virus replication for vaccine development |
US10457708B2 (en) | 2015-07-07 | 2019-10-29 | Janssen Vaccines & Prevention B.V. | Stabilized soluble pre-fusion RSV F polypeptides |
PL3319633T3 (pl) | 2015-07-07 | 2021-04-19 | Janssen Vaccines & Prevention B.V. | Szczepionka przeciwko rsv |
EA036412B1 (ru) | 2015-10-06 | 2020-11-09 | Янссен Вэксинс Энд Превеншн Б.В. | Способ обеспечения защиты аденовируса от разрушения, вызванного взаимодействием с пластиком, и применение 2-гидроксипропил--циклодекстрина для защиты аденовируса |
US11197925B2 (en) | 2016-02-19 | 2021-12-14 | Wisconsin Alumni Research Foundation (Warf) | Influenza B virus replication for vaccine development |
AU2017248021B2 (en) | 2016-04-05 | 2021-08-12 | Janssen Vaccines & Prevention B.V. | Stabilized soluble pre-fusion RSV F proteins |
WO2017174564A1 (en) | 2016-04-05 | 2017-10-12 | Janssen Vaccines & Prevention B.V. | Vaccine against rsv |
WO2017184590A1 (en) | 2016-04-18 | 2017-10-26 | The Broad Institute Inc. | Improved hla epitope prediction |
JP2019523644A (ja) | 2016-05-30 | 2019-08-29 | ヤンセン ファッシンズ アンド プリベンション ベーフェーJanssen Vaccines & Prevention B.V. | 安定化された融合前rsv fタンパク質 |
EP3472327B1 (de) | 2016-06-20 | 2020-08-19 | Janssen Vaccines & Prevention B.V. | Potenter und ausbalancierter bidirektionaler promotor |
JP7229151B2 (ja) | 2016-07-14 | 2023-02-27 | ヤンセン ファッシンズ アンド プリベンション ベーフェー | Hpvワクチン |
WO2018140391A1 (en) | 2017-01-24 | 2018-08-02 | The Broad Institute, Inc. | Compositions and methods for detecting a mutant variant of a polynucleotide |
ES2965475T3 (es) | 2017-02-12 | 2024-04-15 | Biontech Us Inc | Métodos y composiciones basados en HLA y usos de los mismos |
CA3061278A1 (en) | 2017-05-17 | 2018-11-22 | Janssen Vaccines & Prevention B.V. | Methods and compositions for inducing protective immunity against rsv infection |
WO2019053109A1 (en) | 2017-09-15 | 2019-03-21 | Janssen Vaccines & Prevention B.V. | METHOD FOR SAFE INDUCTION OF IMMUNITY AGAINST RSV |
BR112020008652A2 (pt) | 2017-11-03 | 2020-11-10 | Takeda Vaccines, Inc. | vacinas e composições imunogênicas contra zika e métodos de uso das mesmas |
WO2019118480A1 (en) | 2017-12-11 | 2019-06-20 | Beth Israel Deaconess Medical Center, Inc. | Recombinant adenoviruses and uses thereof |
WO2019126186A1 (en) | 2017-12-18 | 2019-06-27 | Neon Therapeutics, Inc. | Neoantigens and uses thereof |
CN108342362A (zh) * | 2018-01-31 | 2018-07-31 | 武汉枢密脑科学技术有限公司 | 一种用于扩增重组犬腺病毒cav2的稳定细胞系mdck及其构建方法 |
WO2020072700A1 (en) | 2018-10-02 | 2020-04-09 | Dana-Farber Cancer Institute, Inc. | Hla single allele lines |
US20220062394A1 (en) | 2018-12-17 | 2022-03-03 | The Broad Institute, Inc. | Methods for identifying neoantigens |
MX2021007556A (es) | 2018-12-21 | 2021-09-10 | Biontech Us Inc | Método y sistemas de predicción de epítopos específicos de hla de clase ii y caracterización de células t cd4+. |
JP2022527235A (ja) | 2019-01-23 | 2022-06-01 | 義裕 河岡 | インフルエンザウイルスにおける付加的遺伝子に遺伝的安定性を付与する突然変異 |
CN113874496A (zh) | 2019-02-08 | 2021-12-31 | 威斯康星校友研究基金会(Warf) | 人源化细胞系 |
CN114929269A (zh) | 2019-05-01 | 2022-08-19 | 威斯康星校友研究基金会(Warf) | 用于疫苗开发的改进的流感病毒复制 |
CA3137652A1 (en) | 2019-05-08 | 2020-11-12 | Takeda Vaccines, Inc. | Inactivated virus compositions and zika vaccine formulations |
AU2020275910A1 (en) | 2019-05-15 | 2021-11-04 | Janssen Vaccines & Prevention B.V. | Prophylactic treatment of respiratory syncytial virus infection with an adenovirus based vaccine |
WO2020229577A1 (en) | 2019-05-15 | 2020-11-19 | Janssen Vaccines & Prevention B.V. | Co-administration of seasonal influenza vaccine and an adenovirus based respiratory syncytial virus vaccine |
US11807872B2 (en) | 2019-08-27 | 2023-11-07 | Wisconsin Alumni Research Foundation (Warf) | Recombinant influenza viruses with stabilized HA for replication in eggs |
CN117083081A (zh) | 2020-12-14 | 2023-11-17 | 百欧恩泰美国公司 | 用于癌症免疫疗法的组织特异性抗原 |
WO2023154043A1 (en) | 2022-02-09 | 2023-08-17 | Takeda Vaccines, Inc. | Zika vaccines and immunogenic compositions, and methods of using the same |
US20230399625A1 (en) * | 2022-06-09 | 2023-12-14 | CHO Plus, Inc. | Cell hybrids as host cells for high efficiency production of gene therapy vectors and viral vaccines |
WO2024015892A1 (en) | 2022-07-13 | 2024-01-18 | The Broad Institute, Inc. | Hla-ii immunopeptidome methods and systems for antigen discovery |
EP4338727A1 (de) | 2022-09-14 | 2024-03-20 | Roquette Freres | Adenovirus-formulierungen |
Family Cites Families (122)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4593002A (en) | 1982-01-11 | 1986-06-03 | Salk Institute Biotechnology/Industrial Associates, Inc. | Viruses with recombinant surface proteins |
US4487829A (en) | 1982-03-23 | 1984-12-11 | Massachusetts Institute Of Technology | Production and use of monoclonal antibodies against adenoviruses |
US4792525A (en) | 1982-08-04 | 1988-12-20 | La Jolla Cancer Research Foundation | Tetrapeptide |
US4578079A (en) | 1982-08-04 | 1986-03-25 | La Jolla Cancer Research Foundation | Tetrapeptide |
US4589881A (en) | 1982-08-04 | 1986-05-20 | La Jolla Cancer Research Foundation | Polypeptide |
US4517686A (en) | 1982-08-04 | 1985-05-21 | La Jolla Cancer Research Foundation | Polypeptide |
US4797368A (en) | 1985-03-15 | 1989-01-10 | The United States Of America As Represented By The Department Of Health And Human Services | Adeno-associated virus as eukaryotic expression vector |
FR2602790B1 (fr) | 1986-08-13 | 1990-06-01 | Transgene Sa | Expression d'un antigene specifique de tumeur par un virus vecteur recombinant et utilisation de celui-ci pour le traitement preventif ou curatif de la tumeur correspondante |
US5166320A (en) | 1987-04-22 | 1992-11-24 | University Of Connecticut | Carrier system and method for the introduction of genes into mammalian cells |
US4956281A (en) | 1987-06-03 | 1990-09-11 | Biogen, Inc. | DNA sequences, recombinant DNA molecules and processes for producing lymphocyte function associated antigen-3 |
US5024939A (en) | 1987-07-09 | 1991-06-18 | Genentech, Inc. | Transient expression system for producing recombinant protein |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5204445A (en) | 1988-10-03 | 1993-04-20 | The Scripps Research Institute | Peptides and antibodies that inhibit integrin-ligand binding |
US5096815A (en) | 1989-01-06 | 1992-03-17 | Protein Engineering Corporation | Generation and selection of novel dna-binding proteins and polypeptides |
US5198346A (en) | 1989-01-06 | 1993-03-30 | Protein Engineering Corp. | Generation and selection of novel DNA-binding proteins and polypeptides |
US5223394A (en) | 1989-04-10 | 1993-06-29 | Biogen, Inc. | Recombinant dna molecule comprising lymphocyte function-associated antigen 3 phosphatidylinositol linkage signal sequence |
WO1991000360A1 (en) | 1989-06-29 | 1991-01-10 | Medarex, Inc. | Bispecific reagents for aids therapy |
US5240846A (en) | 1989-08-22 | 1993-08-31 | The Regents Of The University Of Michigan | Gene therapy vector for cystic fibrosis |
US5332567A (en) | 1989-08-24 | 1994-07-26 | Immunomedics | Detection and treatment of infections with immunoconjugates |
US5436146A (en) | 1989-09-07 | 1995-07-25 | The Trustees Of Princeton University | Helper-free stocks of recombinant adeno-associated virus vectors |
JP3360108B2 (ja) | 1989-10-20 | 2002-12-24 | メダレックス インク. | 二つのエフェクター機能を有する二元特異性異種抗体 |
JPH05504677A (ja) | 1989-10-20 | 1993-07-22 | トラスティーズ オブ ダートマス カレッジ | IgAレセプターに特異的なモノクロナール抗体 |
WO1991018088A1 (en) | 1990-05-23 | 1991-11-28 | The United States Of America, Represented By The Secretary, United States Department Of Commerce | Adeno-associated virus (aav)-based eucaryotic vectors |
US5349053A (en) | 1990-06-01 | 1994-09-20 | Protein Design Labs, Inc. | Chimeric ligand/immunoglobulin molecules and their uses |
US5246921A (en) | 1990-06-26 | 1993-09-21 | The Wistar Institute Of Anatomy And Biology | Method for treating leukemias |
GB2246779B (en) | 1990-08-03 | 1994-08-17 | Delta Biotechnology Ltd | Tumour-associated protease inhibitors targeted to tumour cells |
GB9101550D0 (en) | 1991-01-24 | 1991-03-06 | Mastico Robert A | Antigen-presenting chimaeric protein |
WO1993003769A1 (en) | 1991-08-20 | 1993-03-04 | THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTEMENT OF HEALTH AND HUMAN SERVICES | Adenovirus mediated transfer of genes to the gastrointestinal tract |
FR2681786A1 (fr) | 1991-09-27 | 1993-04-02 | Centre Nat Rech Scient | Vecteurs recombinants d'origine virale, leur procede d'obtention et leur utilisation pour l'expression de polypeptides dans des cellules musculaires. |
NZ244306A (en) | 1991-09-30 | 1995-07-26 | Boehringer Ingelheim Int | Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation |
IL103059A0 (en) | 1991-09-30 | 1993-02-21 | Boehringer Ingelheim Int | Conjugates for introducing nucleic acid into higher eucaryotic cells |
US5521291A (en) | 1991-09-30 | 1996-05-28 | Boehringer Ingelheim International, Gmbh | Conjugates for introducing nucleic acid into higher eucaryotic cells |
DE69334238D1 (de) | 1992-09-25 | 2008-09-25 | Aventis Pharma Sa | Adenovirus vektoren für die übertragung fremder gene in zellen des zentralen nervensystems, insbesondere im gehirn |
GB9223084D0 (en) | 1992-11-04 | 1992-12-16 | Imp Cancer Res Tech | Compounds to target cells |
ATE307212T1 (de) | 1992-11-18 | 2005-11-15 | Arch Dev Corp | Adenovirus-gelenkter gen-transfer zum herz-und glatten vaskulären muskel |
GB9300686D0 (en) | 1993-01-15 | 1993-03-03 | Imp Cancer Res Tech | Compounds for targeting |
WO1994017832A1 (en) | 1993-02-09 | 1994-08-18 | The Scripps Research Institute | Targeting and delivery of genes and antiviral agents into cells by the adenovirus penton |
DE4311651A1 (de) | 1993-04-08 | 1994-10-13 | Boehringer Ingelheim Int | Virus für den Transport von Fremd-DNA in höhere eukaryotische Zellen |
EP0698109B1 (de) | 1993-05-10 | 2002-07-31 | The Regents Of The University Of Michigan | Gentransfer zu den pankreatischen epithelzellen |
US5834256A (en) * | 1993-06-11 | 1998-11-10 | Cell Genesys, Inc. | Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells |
US5543328A (en) | 1993-08-13 | 1996-08-06 | Genetic Therapy, Inc. | Adenoviruses having modified fiber proteins |
EP0716711A1 (de) | 1993-09-03 | 1996-06-19 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Vektor für leber-gentherapie |
US5552311A (en) | 1993-09-14 | 1996-09-03 | University Of Alabama At Birmingham Research Foundation | Purine nucleoside phosphorylase gene therapy for human malignancy |
US5534423A (en) | 1993-10-08 | 1996-07-09 | Regents Of The University Of Michigan | Methods of increasing rates of infection by directing motion of vectors |
FR2712812B1 (fr) | 1993-11-23 | 1996-02-09 | Centre Nat Rech Scient | Composition pour la production de produits thérapeutiques in vivo. |
IT1271461B (it) | 1993-12-01 | 1997-05-28 | Menarini Ricerche Sud Spa | Anticorpo monoclonale bispecifico anti-cd3/anti-egfr,processo per la produzione e suo uso. |
US5443953A (en) | 1993-12-08 | 1995-08-22 | Immunomedics, Inc. | Preparation and use of immunoconjugates |
US5928944A (en) | 1994-02-04 | 1999-07-27 | The United States Of America As Represented By The Department Of Health And Human Services | Method of adenoviral-medicated cell transfection |
US6312699B1 (en) | 1994-03-28 | 2001-11-06 | Uab Research Foundation | Ligands added to adenovirus fiber |
US7252989B1 (en) | 1994-04-04 | 2007-08-07 | Board Of Regents, The University Of Texas System | Adenovirus supervector system |
CA2158926A1 (en) | 1994-05-13 | 1995-11-14 | Douglas J. Jolly | Compositions and methods for targeting gene delivery vehicles |
US5571531A (en) | 1994-05-18 | 1996-11-05 | Mcmaster University | Microparticle delivery system with a functionalized silicone bonded to the matrix |
US5570975A (en) | 1994-06-27 | 1996-11-05 | Reinert, Sr.; Gary L. | Metal foundation push-it and installation apparatus and method |
FR2721943B1 (fr) | 1994-06-29 | 1996-08-02 | Rhone Poulenc Rorer Sa | Adenovirus comprenant un gene codant pour une superoxyde dismutase |
US5846782A (en) | 1995-11-28 | 1998-12-08 | Genvec, Inc. | Targeting adenovirus with use of constrained peptide motifs |
US5559099A (en) | 1994-09-08 | 1996-09-24 | Genvec, Inc. | Penton base protein and methods of using same |
CA2199609A1 (en) | 1994-09-09 | 1996-03-14 | Errol B. Desouza | Interleukin-1 type 3 receptors |
FR2724846B1 (fr) | 1994-09-27 | 1996-12-20 | Rhone Poulenc Rorer Sa | Methode de traitement des cancers par regulation de l'activite des proteines ras |
FR2725726B1 (fr) | 1994-10-17 | 1997-01-03 | Centre Nat Rech Scient | Vecteurs viraux et utilisation en therapie genique |
US5856152A (en) | 1994-10-28 | 1999-01-05 | The Trustees Of The University Of Pennsylvania | Hybrid adenovirus-AAV vector and methods of use therefor |
DE69534166T2 (de) | 1994-10-28 | 2006-03-09 | Trustees Of The University Of Pennsylvania | Rekombinanter adenovirus und methoden zu dessen verwendung |
WO1996014837A1 (en) | 1994-11-09 | 1996-05-23 | Genetic Therapy, Inc. | Gene therapy for hypercholesterolemia |
WO1996017073A1 (fr) | 1994-11-29 | 1996-06-06 | Takara Shuzo Co., Ltd. | Procede pour la production de cellules transformees |
FR2727867B1 (fr) | 1994-12-13 | 1997-01-31 | Rhone Poulenc Rorer Sa | Transfert de genes dans les motoneurones medullaires au moyen de vecteurs adenoviraux |
US5880102A (en) * | 1995-01-17 | 1999-03-09 | Duke University | Adenoviral vector system |
AUPN107195A0 (en) | 1995-02-10 | 1995-03-09 | Withers, Graham Rex | Metal matrix forming method and apparatus |
US6127525A (en) | 1995-02-21 | 2000-10-03 | Cornell Research Foundation, Inc. | Chimeric adenoviral coat protein and methods of using same |
US5770442A (en) | 1995-02-21 | 1998-06-23 | Cornell Research Foundation, Inc. | Chimeric adenoviral fiber protein and methods of using same |
AU5703796A (en) | 1995-05-10 | 1996-11-29 | Introgene B.V. | Improved retroviral vectors, especially suitable for gene th erapy |
US6265212B1 (en) | 1995-06-15 | 2001-07-24 | Introgene B.V. | Packaging systems for human recombinant adenovirus to be used in gene therapy |
SI0833934T2 (sl) * | 1995-06-15 | 2013-04-30 | Crucell Holland B.V. | Pakirni sistemi za humani rekombinantni adenovirus za uporabo v genski terapiji |
US5622699A (en) | 1995-09-11 | 1997-04-22 | La Jolla Cancer Research Foundation | Method of identifying molecules that home to a selected organ in vivo |
US5837511A (en) | 1995-10-02 | 1998-11-17 | Cornell Research Foundation, Inc. | Non-group C adenoviral vectors |
WO1997020575A1 (en) | 1995-12-08 | 1997-06-12 | The University Of Alabama At Birmingham Research Foundation | Targeted adenovirus vectors |
CA2251738A1 (en) | 1996-04-16 | 1997-10-23 | Immusol Incorporated | Targeted viral vectors |
WO1998011221A2 (en) | 1996-09-13 | 1998-03-19 | Dana-Farber Cancer Institute | Car, a novel coxsackievirus and adenovirus receptor |
EP1471146B1 (de) | 1996-09-25 | 2009-01-07 | Novartis AG | Verpackungszellinien in der Verwendung zur Erleichterung der Entwicklung hocheffizienter adenoviraler Vektoren |
US5994132A (en) | 1996-10-23 | 1999-11-30 | University Of Michigan | Adenovirus vectors |
US5877011A (en) | 1996-11-20 | 1999-03-02 | Genzyme Corporation | Chimeric adenoviral vectors |
US5922315A (en) | 1997-01-24 | 1999-07-13 | Genetic Therapy, Inc. | Adenoviruses having altered hexon proteins |
AU6691098A (en) | 1997-03-07 | 1998-09-22 | Wistar Institute Of Anatomy & Biology, The | Method and compositions for healing tissue defects and inducing hypervascularityin mammalian tissue |
US6100086A (en) | 1997-04-14 | 2000-08-08 | Genzyme Corporation | Transgene expression systems |
CN1680442A (zh) | 1997-04-25 | 2005-10-12 | 科莱特诺医疗公司 | 截短的vegf相关蛋白质 |
AU743051B2 (en) | 1997-05-08 | 2002-01-17 | Genetic Therapy, Inc. | Gene transfer with adenoviruses having modified fiber proteins |
US5849561A (en) * | 1997-05-22 | 1998-12-15 | Cornell Research Foundation, Inc. | Method for the production of non-group C adenoviral vectors |
DE19754103A1 (de) * | 1997-12-08 | 1999-06-10 | Hepavec Ag Fuer Gentherapie | Verpackungszellinie zur Produktion von E1 deletierten Adenoviren |
EP1042494A1 (de) * | 1997-12-23 | 2000-10-11 | Introgene B.V. | Chimere rekombinante vektoren abgeleitet von adeno-assoziiertem virus und adenovirus für die chromosomale integration von fremd-dns in zielzellen |
US6287857B1 (en) | 1998-02-09 | 2001-09-11 | Genzyme Corporation | Nucleic acid delivery vehicles |
DE19807265C2 (de) * | 1998-02-20 | 2000-01-05 | Centeon Pharma Gmbh | Adenoviraler Transfervektor für den Gentransport einer DNA-Sequenz |
WO1999047180A1 (en) | 1998-03-20 | 1999-09-23 | Genzyme Corporation | Chimeric adenoviral vectors for targeted gene delivery |
US6670188B1 (en) | 1998-04-24 | 2003-12-30 | Crucell Holland B.V. | Packaging systems for human recombinant adenovirus to be used in gene therapy |
IT1299201B1 (it) | 1998-05-08 | 2000-02-29 | San Raffaele Centro Fond | Fibroblasti modificati geneticamente e loro uso |
EP0959136A1 (de) | 1998-05-20 | 1999-11-24 | Introgene B.V. | Bei einem transporter von kationischen Aminosaüren zielgerichtete Darreichung |
US6413776B1 (en) | 1998-06-12 | 2002-07-02 | Galapagos Geonomics N.V. | High throughput screening of gene function using adenoviral libraries for functional genomics applications |
US20030017138A1 (en) | 1998-07-08 | 2003-01-23 | Menzo Havenga | Chimeric adenoviruses |
WO2000024730A1 (en) | 1998-10-28 | 2000-05-04 | The University Of British Columbia | Organic vanadium(iii) complexes and their use |
US6929946B1 (en) | 1998-11-20 | 2005-08-16 | Crucell Holland B.V. | Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells |
EP1020529B1 (de) | 1998-11-20 | 2005-06-01 | Crucell Holland B.V. | Genverabreichende Vektoren mit Gewebetropismus für glatte Muskelzellen und/oder Endothelzellen |
IL133032A (en) | 1998-11-20 | 2007-06-03 | Introgene Bv | Adenoviral gene delivery vectors provided with a tissue tropism for smooth muscle cells and /or endothelial cells |
EP1016726A1 (de) | 1998-12-30 | 2000-07-05 | Introgene B.V. | Gentherapie zur Förderung der Angiogenesis |
US6869936B1 (en) | 1999-03-04 | 2005-03-22 | Crucell Holland B.V. | Means and methods for fibroblast-like or macrophage-like cell transduction |
WO2000052186A1 (en) | 1999-03-04 | 2000-09-08 | Introgene B.V. | Means and methods for fibroblast-like or macrophage-like cell transduction |
DE19918023A1 (de) * | 1999-03-16 | 2000-09-21 | Guenter Cichon | Verfahren zur Herstellung von leberzellabgleiteten Verpackungszelllinien und ihre Verwendung |
US7604960B2 (en) | 1999-04-15 | 2009-10-20 | Crucell Holland B.V. | Transient protein expression methods |
ATE519854T1 (de) | 1999-05-17 | 2011-08-15 | Crucell Holland Bv | Rekombinantes adenovirus auf basis von serotyp 48 (ad48). |
US6913922B1 (en) | 1999-05-18 | 2005-07-05 | Crucell Holland B.V. | Serotype of adenovirus and uses thereof |
US6492169B1 (en) * | 1999-05-18 | 2002-12-10 | Crucell Holland, B.V. | Complementing cell lines |
EP1067188A1 (de) | 1999-07-08 | 2001-01-10 | Introgene B.V. | Infektion mit chimärischen Adenoviren der Zellen die für den Adenoviren Serotyp 5 Coxsacki Adenoviren Rezeptor (CAR) negativ sind |
WO2001030158A1 (fr) | 1999-10-28 | 2001-05-03 | Research Association For Improvement Of Wood Quality | Emulsion d'huile de creosote et procede de production associe |
EP1307573B1 (de) | 2000-08-10 | 2006-01-04 | Crucell Holland B.V. | Adenovirenvektoren zur transduktion der chondrozyten |
EP1322774A2 (de) | 2000-09-20 | 2003-07-02 | Crucell Holland B.V. | Transduktion von dendritischen zellen durch verwendung der adenovirenvektoren |
DE60138403D1 (de) | 2000-09-26 | 2009-05-28 | Crucell Holland Bv | Adenovirale vektoren für die übertragung von genen in zellen der skelettmuskulatur oder myoblasten |
EP1191104A1 (de) | 2000-09-26 | 2002-03-27 | Introgene B.V. | Genträger und deren Verwendung zur Herstellung von Arzneimitteln und/oder Impfstöffen |
US6905678B2 (en) | 2001-07-07 | 2005-06-14 | Crucell Holland B.V. | Gene delivery vectors with cell type specificity for mesenchymal stem cells |
CA2477954C (en) | 2002-04-25 | 2012-07-10 | Crucell Holland B.V. | Means and methods for the production of adenovirus vectors |
CA2478508C (en) | 2002-04-25 | 2013-07-02 | Crucell Holland B.V. | Stable adenoviral vectors and methods for propagation thereof |
US20080153083A1 (en) | 2003-10-23 | 2008-06-26 | Crucell Holland B.V. | Settings for recombinant adenoviral-based vaccines |
EP1553983A2 (de) | 2002-10-23 | 2005-07-20 | Crucell Holland B.V. | Einstellung für rekombinante adenovirus-basierte impfstoffe |
US7026164B2 (en) * | 2003-07-03 | 2006-04-11 | Cell Genesys, Inc. | Adenovirus packaging cell lines |
DK1670925T3 (da) | 2003-10-02 | 2013-07-08 | Crucell Holland Bv | Pakningsceller til rekombinat adenovirus |
AP2351A (en) | 2004-10-13 | 2012-01-25 | Crucell Holland Bv | Improved adenoviral vectors and uses thereof. |
SG159554A1 (en) | 2004-11-16 | 2010-03-30 | Crucell Holland Bv | Multivalent vaccines comprising recombinant viral vectors |
-
2000
- 2000-11-15 US US09/713,678 patent/US6492169B1/en not_active Expired - Lifetime
-
2001
- 2001-11-14 DK DK01996603T patent/DK1349926T3/da active
- 2001-11-14 EP EP01996603A patent/EP1349926B1/de not_active Expired - Lifetime
- 2001-11-14 WO PCT/NL2001/000824 patent/WO2002040665A2/en active IP Right Grant
- 2001-11-14 DE DE60121471T patent/DE60121471T2/de not_active Expired - Lifetime
- 2001-11-14 ES ES01996603T patent/ES2267864T3/es not_active Expired - Lifetime
- 2001-11-14 CA CA2428739A patent/CA2428739C/en not_active Expired - Fee Related
- 2001-11-14 NZ NZ525997A patent/NZ525997A/en not_active IP Right Cessation
- 2001-11-14 AU AU1856902A patent/AU1856902A/xx active Pending
- 2001-11-14 AU AU2002218569A patent/AU2002218569B2/en not_active Ceased
- 2001-11-14 AT AT01996603T patent/ATE332965T1/de active
- 2001-11-14 JP JP2002543660A patent/JP4402881B2/ja not_active Expired - Lifetime
- 2001-11-14 PT PT01996603T patent/PT1349926E/pt unknown
- 2001-11-15 US US10/002,750 patent/US6974695B2/en not_active Expired - Lifetime
-
2002
- 2002-06-04 US US10/164,085 patent/US6869794B2/en not_active Expired - Lifetime
- 2002-10-15 US US10/272,041 patent/US7250293B2/en not_active Expired - Lifetime
-
2005
- 2005-06-24 US US11/165,697 patent/US7344883B2/en not_active Expired - Lifetime
-
2006
- 2006-09-15 CY CY20061101321T patent/CY1105232T1/el unknown
-
2007
- 2007-04-11 US US11/786,409 patent/US20080199433A1/en not_active Abandoned
-
2012
- 2012-03-27 US US13/431,806 patent/US20130156736A1/en not_active Abandoned
-
2014
- 2014-07-18 US US14/335,679 patent/US9228205B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
DE60121471D1 (de) | 2006-08-24 |
US20030119192A1 (en) | 2003-06-26 |
NZ525997A (en) | 2005-10-28 |
DE60121471T2 (de) | 2007-02-08 |
WO2002040665A2 (en) | 2002-05-23 |
AU2002218569B2 (en) | 2007-04-05 |
PT1349926E (pt) | 2006-12-29 |
US20030171336A1 (en) | 2003-09-11 |
US6869794B2 (en) | 2005-03-22 |
JP2004513657A (ja) | 2004-05-13 |
EP1349926A2 (de) | 2003-10-08 |
US20030185801A1 (en) | 2003-10-02 |
EP1349926B1 (de) | 2006-07-12 |
ES2267864T3 (es) | 2007-03-16 |
US7344883B2 (en) | 2008-03-18 |
US7250293B2 (en) | 2007-07-31 |
US6974695B2 (en) | 2005-12-13 |
WO2002040665A3 (en) | 2002-10-17 |
CA2428739A1 (en) | 2002-05-23 |
CA2428739C (en) | 2010-11-16 |
US20080199433A1 (en) | 2008-08-21 |
CY1105232T1 (el) | 2010-03-03 |
DK1349926T3 (da) | 2006-10-30 |
JP4402881B2 (ja) | 2010-01-20 |
AU1856902A (en) | 2002-05-27 |
US20130156736A1 (en) | 2013-06-20 |
US20050277194A1 (en) | 2005-12-15 |
US6492169B1 (en) | 2002-12-10 |
US9228205B2 (en) | 2016-01-05 |
US20150010952A1 (en) | 2015-01-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1349926T3 (da) | Komplementerende cellelinier | |
US20190345204A1 (en) | Oncolytic adenoviruses for treating cancer | |
Tatsis et al. | Adenoviruses as vaccine vectors | |
ES2750305T3 (es) | Mutantes de E1A y E1B de adenovirus selectivos de tumor | |
AU745560B2 (en) | Adenovirus vectors specific for cells expressing alpha-fetoprotein and methods of use thereof | |
ATE403736T1 (de) | Onkolytische adenovirale vektoren | |
CY1107762T1 (el) | Αγωγη του καρκινου του τραχηλου της μητρας | |
ES2821876T3 (es) | Promotor bidireccional potente y equilibrado | |
EP2137301B1 (de) | Adenovirus mit mutationen in der domäne des e3-19k-proteins zur retention im endoplasmatischen retikulum und verwendung in der krebsbehandlung | |
AU2010246273B2 (en) | Compositions and methods for enhancing antigen-specific immune responses | |
EA027784B1 (ru) | Комбинированная вакцина против кори и вируса папилломы человека | |
Backström et al. | Adenovirus L4-22K stimulates major late transcription by a mechanism requiring the intragenic late-specific transcription factor-binding site | |
Sirena et al. | The nucleotide sequence and a first generation gene transfer vector of species B human adenovirus serotype 3 | |
MX2022016287A (es) | Secuencias de acidos nucleicos y de aminoacidos de adenovirus de gorila, vectores que contienen las mismas y usos de las mismas. | |
Mirazimi et al. | ATP is required for correct folding and disulfide bond formation of rotavirus VP7 | |
Munemitsu et al. | Biosynthesis of reovirus-specified polypeptides multiplication rate but not yield of reovirus serotypes 1 and 3 correlates with the level of virus-mediated inhibition of cellular protein synthesis | |
Chatellard et al. | Synthesis of human adenovirus type 2 fiber protein in Escherichia coli cells | |
ES2733593T3 (es) | Adenovirus recombinante que expresa dos transgenes con un promotor bidireccional | |
ES2829272T3 (es) | Promotor bidireccional potente y equilibrado | |
KR20070073299A (ko) | 복제가능 아데노바이러스 생성이 억제되는 재조합아데노바이러스 벡터 | |
WO2004011489A3 (fr) | Adenovirus modifies pour changer leur tropisme, de preference pour le ciblage des lymphocytes b ou des cellules ovariennes | |
BR9905677A (pt) | Desenvolvimento de um vetor de expressão do vìrus recombinante modificado - mva - (modified vaccina ankara) portando o gene e2 do vìrus de papiloma bovino e seu uso em terapia de tumores provocados pelo vìrus do papiloma | |
WO2002081716A1 (en) | Improved ovine adenovirus vector |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1349926 Country of ref document: EP |